In summary, the results of the present study indicate that in AML cells, MCL-1 antagonists trigger a rebound stabilization and accumulation of this protein by disrupting its degradative ubiquitination, leading to attenuation of cell death.30 Importantly, Src inhibitors oppose this process, resulting in MCL-1 down-regulation and highly synergistic anti-leukemic effects. This evidence concerns the gene MCL1 and acute myeloid leukemia.